NasdaqCM - Nasdaq Real Time Price USD

Nektar Therapeutics (NKTR)

1.3200 0.0000 (0.00%)
At close: April 26 at 4:00 PM EDT
1.3100 -0.01 (-0.76%)
After hours: April 26 at 7:17 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
90,122.0000
90,122.0000
92,055.0000
101,907.0000
152,915.0000
Cost of Revenue
33,768.0000
33,768.0000
21,635.0000
24,897.0000
19,477.0000
Gross Profit
56,354.0000
56,354.0000
70,420.0000
77,010.0000
133,438.0000
Operating Expense
191,579.0000
191,579.0000
310,656.0000
523,113.0000
513,360.0000
Operating Income
-135,225.0000
-135,225.0000
-240,236.0000
-446,103.0000
-379,922.0000
Net Non Operating Interest Income Expense
-6,325.0000
-6,325.0000
-22,128.0000
-44,582.0000
-18,836.0000
Other Income Expense
-134,706.0000
-134,706.0000
-102,619.0000
-32,595.0000
-45,189.0000
Pretax Income
-276,256.0000
-276,256.0000
-364,983.0000
-523,280.0000
-443,947.0000
Tax Provision
-200.0000
-200.0000
3,215.0000
557.0000
493.0000
Net Income Common Stockholders
-276,056.0000
-276,056.0000
-368,198.0000
-523,837.0000
-444,440.0000
Diluted NI Available to Com Stockholders
-276,056.0000
-276,056.0000
-368,198.0000
-523,837.0000
-444,440.0000
Basic EPS
-1.45
-1.45
-1.97
-2.86
-2.49
Diluted EPS
-1.45
-1.45
-1.97
-2.86
-2.49
Basic Average Shares
190,001.0000
190,001.0000
187,138.0000
183,298.0000
178,581.0000
Diluted Average Shares
190,001.0000
190,001.0000
187,138.0000
183,298.0000
178,581.0000
Total Operating Income as Reported
-263,684.0000
-263,684.0000
-376,166.0000
-446,103.0000
-425,111.0000
Total Expenses
225,347.0000
225,347.0000
332,291.0000
548,010.0000
532,837.0000
Net Income from Continuing & Discontinued Operation
-276,056.0000
-276,056.0000
-368,198.0000
-523,837.0000
-444,440.0000
Normalized Income
-147,690.0000
-147,690.0000
-287,220.6300
-517,980.2100
-411,452.0300
Interest Income
19,009.0000
19,009.0000
6,783.0000
2,731.0000
18,282.0000
Interest Expense
25,334.0000
25,334.0000
28,911.0000
47,313.0000
37,118.0000
Net Interest Income
-6,325.0000
-6,325.0000
-22,128.0000
-44,582.0000
-18,836.0000
EBIT
-250,922.0000
-250,922.0000
-336,072.0000
-475,967.0000
-406,829.0000
EBITDA
-243,107.0000
-243,107.0000
-323,042.0000
-461,821.0000
-392,647.0000
Reconciled Cost of Revenue
33,768.0000
33,768.0000
21,635.0000
24,897.0000
19,477.0000
Reconciled Depreciation
7,815.0000
7,815.0000
13,030.0000
14,146.0000
14,182.0000
Net Income from Continuing Operation Net Minority Interest
-276,056.0000
-276,056.0000
-368,198.0000
-523,837.0000
-444,440.0000
Total Unusual Items Excluding Goodwill
-128,459.0000
-128,459.0000
-102,503.0000
-8,023.0000
-45,189.0000
Total Unusual Items
-128,459.0000
-128,459.0000
-102,503.0000
-8,023.0000
-45,189.0000
Normalized EBITDA
-114,648.0000
-114,648.0000
-220,539.0000
-453,798.0000
-347,458.0000
Tax Rate for Calcs
0.0000
0.0000
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
-93.0000
-93.0000
-21,525.6300
-2,166.2100
-12,201.0300
12/31/2020 - 5/3/1994

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KZR Kezar Life Sciences, Inc.
0.8049
+1.89%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
BLUE bluebird bio, Inc.
0.9228
+1.13%
 
FGEN FibroGen, Inc.
1.0400
+1.96%
 
NKTX Nkarta, Inc.
6.87
+0.73%
 
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
 
SGMO Sangamo Therapeutics, Inc.
0.5178
+2.94%
 
VERU Veru Inc.
1.2700
+4.96%
 
KPTI Karyopharm Therapeutics Inc.
1.0600
0.00%
 
NUVB Nuvation Bio Inc.
2.6800
+2.29%